ATE469353T1 - Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen - Google Patents
Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungenInfo
- Publication number
- ATE469353T1 ATE469353T1 AT06763552T AT06763552T ATE469353T1 AT E469353 T1 ATE469353 T1 AT E469353T1 AT 06763552 T AT06763552 T AT 06763552T AT 06763552 T AT06763552 T AT 06763552T AT E469353 T1 ATE469353 T1 AT E469353T1
- Authority
- AT
- Austria
- Prior art keywords
- proanp
- probnp
- level
- cardiac
- increased level
- Prior art date
Links
- 208000019622 heart disease Diseases 0.000 title abstract 5
- 230000001154 acute effect Effects 0.000 abstract 4
- 230000000747 cardiac effect Effects 0.000 abstract 4
- 208000020446 Cardiac disease Diseases 0.000 abstract 3
- 230000001684 chronic effect Effects 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 abstract 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 abstract 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 abstract 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 abstract 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 abstract 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 abstract 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical group C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 abstract 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical group C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05012196A EP1731910A1 (de) | 2005-06-07 | 2005-06-07 | Gebrauch von NT-proANP und NT-proBNP für die Diagnose von Herzkrankheiten |
| PCT/EP2006/062957 WO2006131529A1 (en) | 2005-06-07 | 2006-06-07 | Use of nt-proanp and nt-probnp for diagnosing cardiac diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE469353T1 true ATE469353T1 (de) | 2010-06-15 |
Family
ID=34937270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06763552T ATE469353T1 (de) | 2005-06-07 | 2006-06-07 | Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7608418B2 (de) |
| EP (2) | EP1731910A1 (de) |
| JP (1) | JP4828600B2 (de) |
| CN (1) | CN101194167A (de) |
| AT (1) | ATE469353T1 (de) |
| CA (1) | CA2607264A1 (de) |
| DE (1) | DE602006014535D1 (de) |
| WO (1) | WO2006131529A1 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002218026A1 (en) | 2000-11-09 | 2002-05-21 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| DK3072978T3 (en) | 2002-05-09 | 2018-09-17 | Brigham & Womens Hospital Inc | : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER |
| ES2344993T3 (es) * | 2006-03-24 | 2010-09-13 | F. Hoffmann-La Roche Ag | Medios y metodos para la diferenciacion de la necrosis de miocardio aguda y cronica en pacientes sintomaticos. |
| DK2848938T3 (da) | 2006-04-24 | 2017-11-13 | Critical Care Diagnostics Inc | Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer |
| PT2021796E (pt) | 2006-05-01 | 2012-04-19 | Critical Care Diagnostics Inc | Diagnóstico de doença cardiovascular |
| WO2008030122A1 (en) | 2006-09-07 | 2008-03-13 | University Of Otago | Biomarkers |
| CN106908603B (zh) * | 2007-01-25 | 2019-04-02 | 霍夫曼-拉罗奇有限公司 | Igfbp-7在心力衰竭评估中的用途 |
| EP1970709B1 (de) * | 2007-03-06 | 2013-07-10 | Roche Diagnostics GmbH | Verwendung von Peptiden vom Typ BNP zur Vorhersage des Dialysebedarfs |
| DE102007010834A1 (de) * | 2007-03-03 | 2008-09-04 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten |
| DE102007022367A1 (de) * | 2007-05-07 | 2008-11-20 | B.R.A.H.M.S Ag | Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten |
| EP2201383B1 (de) | 2007-10-10 | 2014-01-15 | Roche Diagnostics GmbH | Mittel und verfahren zur überwachung eines myokardinfarkts und dessen behandlung |
| JP2011501113A (ja) * | 2007-10-10 | 2011-01-06 | エフ．ホフマン−ラ ロシュ アーゲー | 急性冠症候群を有する患者での既存の心筋機能不全の評価のためのナトリウム利尿ペプチド／トロポニン比 |
| WO2009104974A2 (en) * | 2008-02-22 | 2009-08-27 | Christopher Joseph Pemberton | Biomarkers |
| AU2009224113B2 (en) | 2008-03-12 | 2013-02-21 | Otago Innovation Limited | Biomarkers |
| JP2011516038A (ja) | 2008-03-12 | 2011-05-26 | オタゴ イノベーション リミテッド | バイオマーカー |
| JP5526122B2 (ja) * | 2008-04-18 | 2014-06-18 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 主要有害心イベントのリスクを予測する方法 |
| JP2011528115A (ja) * | 2008-07-14 | 2011-11-10 | エフ．ホフマン−ラ ロシュ アーゲー | 心不全を有する患者の診断、モニター及び治療の選択のためのマルチマーカーパネル |
| EP2376919B1 (de) * | 2008-12-08 | 2015-04-29 | Alere San Diego, Inc. | Kombinierte natriuretische peptidtests |
| CA2780301A1 (en) * | 2009-11-13 | 2011-05-19 | Bg Medicine, Inc. | Risk factors and prediction of myocardial infarction |
| CA2780965C (en) * | 2009-11-27 | 2019-06-04 | F. Hoffmann-La Roche Ag | Method for diagnosing and monitoring cardiac ischemia in patients with acute chest pain and without myocardial infarction |
| US20110306148A1 (en) | 2010-06-14 | 2011-12-15 | Siemens Healthcare Diagnostics Inc. | Composition for use as an assay reagent |
| DK2596010T3 (en) | 2010-07-19 | 2017-07-31 | Otago Innovation Ltd | SIGNAL biomarkers |
| US8728742B2 (en) | 2011-03-17 | 2014-05-20 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| WO2013013758A1 (en) * | 2011-07-28 | 2013-01-31 | B.R.A.H.M.S. Gmbh | Mid-regional pro-atrial natriuretic peptide (pro-anp) for the identification patients with atrial fibrillation with an onset of less than 48 hours ago |
| WO2013053076A1 (en) * | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| CN103998938B (zh) | 2011-10-17 | 2016-06-15 | 霍夫曼-拉罗奇有限公司 | 风险患者和中风原因的基于肌钙蛋白和bnp的诊断 |
| EP2594940A1 (de) * | 2011-11-16 | 2013-05-22 | Koninklijke Philips Electronics N.V. | Partikelabstoßung zur Verbesserung des Oberflächenkontakts in Magnetpartikelimmuntests |
| EP3290924B1 (de) * | 2011-12-01 | 2021-10-13 | Roche Diagnostics GmbH | Nt-pro-anp und nt-pro-bnp zur diagnose eines schlaganfalls |
| US10114028B2 (en) | 2012-03-20 | 2018-10-30 | Upstream Medical Technologies Limited | Biomarkers for pneumonia and acute decompensated heart failure |
| JP6450679B2 (ja) | 2012-08-21 | 2019-01-09 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | マルチマーカーリスク層別化 |
| CN103304665A (zh) * | 2013-05-21 | 2013-09-18 | 上海贝西生物科技有限公司 | 一种抗氨基末端脑利钠肽前体单克隆抗体及其应用 |
| WO2015168145A1 (en) * | 2014-04-28 | 2015-11-05 | Penn Marc S | Sdf-1 delivery for treating advanced ischemic cardiomyopathy |
| CN105085659B (zh) * | 2014-05-20 | 2021-02-19 | 深圳大学 | 一种重组利钠肽及其制备方法 |
| WO2019077082A1 (en) * | 2017-10-18 | 2019-04-25 | Adrenomed Ag | SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM) |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR005600A0 (en) * | 2000-09-12 | 2000-10-05 | University Of Sydney, The | Diagnostic assay |
| US6461828B1 (en) * | 2001-09-04 | 2002-10-08 | Syn X Pharma | Conjunctive analysis of biological marker expression for diagnosing organ failure |
| MXPA03004105A (es) * | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
| GB2403533A (en) * | 2003-06-30 | 2005-01-05 | Orion Corp | Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof |
| US7432107B2 (en) * | 2005-01-24 | 2008-10-07 | Roche Diagnostics Operations, Inc. | Cardiac hormones for assessing cardiovascular risk |
| JP4828550B2 (ja) * | 2005-02-17 | 2011-11-30 | エフ．ホフマン−ラ ロシュ アーゲー | 心機能障害を診断するためのＮＴ−ｐｒｏＡＮＰ／ＮＴ−ｐｒｏＢＮＰ比の使用 |
| US20080221033A1 (en) * | 2005-07-29 | 2008-09-11 | Koninklijke Philips Electronics N. V. | Monitoring of Cardiac Natriuretic Peptides During Diagnosis, Management, and Treatment of Cardiac Diseases |
| DK2848938T3 (da) * | 2006-04-24 | 2017-11-13 | Critical Care Diagnostics Inc | Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer |
| EP1882945A1 (de) * | 2006-07-28 | 2008-01-30 | F.Hoffmann-La Roche Ag | Vorrichtungen und Verfahren zur Differentierung zwischen herz- und lungenbedingten Ursachen für akute Atemnot |
| ATE449966T1 (de) * | 2006-09-15 | 2009-12-15 | Hoffmann La Roche | Biochemische marker für akute lungenembolie |
| ATE476665T1 (de) * | 2006-09-20 | 2010-08-15 | Hoffmann La Roche | Natriurethische peptide und plazenta- wachstumfaktor/löslicher vegf-rezeptor unterscheiden zwischen mit der plazenta verbundener herzdysfunktion und mit herzerkrankung verbundener herzdysfunktion |
| US9012151B2 (en) * | 2006-11-09 | 2015-04-21 | B.R.A.H.M.S. Gmbh | Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin |
-
2005
- 2005-06-07 EP EP05012196A patent/EP1731910A1/de not_active Withdrawn
-
2006
- 2006-06-07 CN CNA2006800204604A patent/CN101194167A/zh active Pending
- 2006-06-07 WO PCT/EP2006/062957 patent/WO2006131529A1/en not_active Ceased
- 2006-06-07 EP EP06763552A patent/EP1889073B1/de not_active Not-in-force
- 2006-06-07 JP JP2008515210A patent/JP4828600B2/ja not_active Expired - Fee Related
- 2006-06-07 CA CA002607264A patent/CA2607264A1/en not_active Abandoned
- 2006-06-07 DE DE602006014535T patent/DE602006014535D1/de active Active
- 2006-06-07 AT AT06763552T patent/ATE469353T1/de not_active IP Right Cessation
-
2007
- 2007-11-27 US US11/945,309 patent/US7608418B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20090042228A1 (en) | 2009-02-12 |
| JP2008542778A (ja) | 2008-11-27 |
| CN101194167A (zh) | 2008-06-04 |
| US7608418B2 (en) | 2009-10-27 |
| WO2006131529A1 (en) | 2006-12-14 |
| JP4828600B2 (ja) | 2011-11-30 |
| DE602006014535D1 (de) | 2010-07-08 |
| CA2607264A1 (en) | 2006-12-14 |
| EP1889073B1 (de) | 2010-05-26 |
| EP1889073A1 (de) | 2008-02-20 |
| EP1731910A1 (de) | 2006-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE469353T1 (de) | Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen | |
| Sugimoto et al. | Cardiac biomarkers in children with congenital heart disease | |
| DE602006011896D1 (de) | Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden | |
| ATE373827T1 (de) | Kombination von markern für diabetes typ 1 und 2 | |
| JP2007523324A5 (de) | ||
| EP1922325A4 (de) | Methoden für die diagnose von demenz und anderen neurologischen erkrankungen | |
| WO2011094535A2 (en) | Biomarkers of aging for detection and treatment of disorders | |
| RU2014145259A (ru) | Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности | |
| ES2954321T3 (es) | Proteína 3 de unión a ácidos grasos para la evaluación de fibrilación auricular (FA) | |
| ATE537454T1 (de) | Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15 | |
| NO20050186L (no) | Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser | |
| EP2227696A1 (de) | Mittel und verfahren zur risikobewertung von patienten bei der einlieferung in die notfallstation auf gdf-15-basis | |
| DE602005001299D1 (de) | Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes | |
| JP5715636B2 (ja) | 循環系事象と虚血性事象を鑑別するためのＮＴ−ｐｒｏＡＮＰおよびＳＦｌｔ−１ | |
| JP2009537797A (ja) | 神経変性疾患の診断及び早期診断のためのｉｎｖｉｔｒｏ方法 | |
| ATE483982T1 (de) | Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen | |
| WO2011062782A3 (en) | Innovative blood platelets biomarker for early diagnosis of alzheimer's disease | |
| DE602007008370D1 (de) | Verfahren zur Detektion der in-vivo-Aktivität von Neurotrypsin, Verwendung des Verfahrens und Verwendung des C-terminal 22-kDa-Fragments als Biomarker bei der Diagnose und Überwachung von Störungen im Zusammenhang mit Neurotrypsin | |
| Meyer et al. | Plasma mid-regional pro-adrenomedullin levels are inversely associated with anxiety but unrelated to depression: Results from the observational DIAST-CHF study in patients with cardiovascular risk factors | |
| JP2019509500A (ja) | 軽度認知障害（ｍｃｉ）の診断、アルツハイマー病（ａｄ）型認知症の発症の予測、ならびにｍｃｉの処置または認知症発症の予防のための薬剤のスクリーニングおよびモニタリング | |
| DE502004012230D1 (de) | Verfahren zur diagnose von erkrankungen unter bestimmung von apolipoprotein c-i | |
| DE602006015964D1 (de) | Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion | |
| US20230176077A1 (en) | Ret (rearranged during transfection) for the assessment of stroke | |
| ES2706539T3 (es) | Método de diagnóstico in vitro de la Enfermedad de Alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo | |
| ES2657087T3 (es) | Monitorización de péptidos natriuréticos cardiacos durante el diagnóstico, manejo y tratamiento de enfermedades cardiacas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |